Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7% – What’s Next?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shares fell 7% during mid-day trading on Wednesday . The company traded as low as $2.19 and last traded at $2.1680. 714,216 shares traded hands during trading, a decline of 59% from the average session volume of 1,727,052 shares. The stock had previously closed at $2.33.

Key Headlines Impacting Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Autolus reported quarterly adjusted earnings of a $0.15 loss per share, better than the $0.21 loss analysts expected. Revenue of $45.69 million also exceeded the $38.56 million consensus estimate, supporting the recent rally. Autolus Therapeutics Trading Up 13.3% After Earnings Beat
• Positive Sentiment: HC Wainwright maintained its Buy rating and $10 price target, implying substantial upside from current levels. The firm raised its FY2026 EPS forecast to a $0.81 loss from a $0.88 loss, and modestly improved its FY2029 and FY2030 forecasts to losses of $0.68 and $0.21 per share, respectively.
• Positive Sentiment: The earnings call and analyst coverage provide investors with additional detail on the company’s financial outlook and operating progress. Autolus Therapeutics Q2 FY2026 Earnings Call Transcript
• Neutral Sentiment: HC Wainwright raised its Q3 2026 EPS estimate to a $0.20 loss from a $0.21 loss, while leaving its FY2026, FY2029 and FY2030 forecasts at $0.81, $0.68 and $0.21 losses, respectively, after the revisions.
• Negative Sentiment: The firm slightly reduced its Q4 2026 EPS estimate to a $0.20 loss from a $0.19 loss. Autolus remains unprofitable, and the broader consensus still expects a full-year loss of approximately $0.86 per share.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on AUTL shares. Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Stock Performance

The company has a fifty day simple moving average of $1.63 and a two-hundred day simple moving average of $1.56. The firm has a market capitalization of $590.88 million, a PE ratio of -2.09 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 152.15% and a negative net margin of 238.66%.The firm had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. On average, equities analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several hedge funds have recently modified their holdings of AUTL. Invesco Ltd. boosted its stake in shares of Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares in the last quarter. Jane Street Group LLC boosted its position in Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after acquiring an additional 91,222 shares in the last quarter. Geode Capital Management LLC boosted its position in Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after acquiring an additional 78,058 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after acquiring an additional 11,289 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Autolus Therapeutics by 2,891.7% in the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after acquiring an additional 942,540 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.